Donck has joined in the new Brussels-based role of vice-president of corporate comms and investor relations from Belgian biotech outfit Innogenetics.
He has overall control of comms, ranging from investor and corporate relations to product media relations and internal comms.
Donck takes the top PR position from former group director of corporate comms Laurence Battaille, who continues to work for UCB - which also makes antiallergics Xyzal and Zyrtec - on a freelance basis.
Donck manages a comms team that has 'around ten to 15' staff globally, he said. Donck left Gent-based Innogenetics last month after around three years. Innogenetics has interests in diagnostics and is working on a hepatitis C vaccine that is in phase II clinical trials.
At Innogenetics, long-serving chief financial officer Wim Ottevaere has resumed control of financial comms.
Family controlled UCB has sold off its chemicals interests as it focuses its business on biopharma. It completed the acquisition of UK biotech firm Celltech last year.
UCB employs more than 8,500 people in more than 40 countries. The firm is also behind products such as ulcerative colitis treatment Dipentum.